Human Pre-Elafin Inhibits a Pseudomonas aeruginosa -Secreted Peptidase and Prevents Its Proliferation in Complex Media
- 1 February 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (2) , 483-490
- https://doi.org/10.1128/aac.00585-07
Abstract
Pseudomonas aeruginosa is a life-threatening opportunist human pathogen frequently associated with lung inflammatory diseases, namely, cystic fibrosis. Like other species, this gram-negative bacteria is increasingly drug resistant. During the past decade, intensive research efforts have been focused on the identification of natural innate defense molecules with broad antimicrobial activities, collectively known as antimicrobial peptides. Human pre-elafin, best characterized as a potent inhibitor of neutrophil elastase with anti-inflammatory properties, was also shown to possess antimicrobial activity against both gram-positive and gram-negative bacteria, including P. aeruginosa . Its mode of action was, however, not known. Using full-length pre-elafin, each domain separately, and mutated variants of pre-elafin with attenuated antipeptidase activity toward neutrophil elastase, we report here that both pre-elafin domains contribute, through distinct mechanisms, to its antibacterial activity against Pseudomonas aeruginosa . Most importantly, we demonstrate that the whey acidic protein (WAP) domain specifically inhibits a secreted peptidase with the characteristics of arginyl peptidase (protease IV). This is the first demonstration that a human WAP-motif protein inhibits a secreted peptidase to prevent bacterial growth in vitro. Since several WAP-motif proteins from various species demonstrate antimicrobial function with variable activities toward bacterial species, we suggest that this mechanism may be more common than initially anticipated.Keywords
This publication has 43 references indexed in Scilit:
- Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysemaBiochemical Journal, 2007
- Protease IV production in Pseudomonas aeruginosa from the lungs of adults with cystic fibrosisJournal of Medical Microbiology, 2006
- Antimicrobial Peptide Therapeutics for Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2005
- Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronicPseudomonas aeruginosa lung infectionPediatric Pulmonology, 2004
- Antimicrobial Activity of Human EPPIN, an Androgen-Regulated, Sperm-Bound Protein with a Whey Acidic Protein Motif1Biology of Reproduction, 2004
- Role of bacterial proteases in pseudomonal and serratial keratitisBiological Chemistry, 2004
- Supernatants of Pseudomonas aeruginosa induce the Pseudomonas‐specific antibiotic elafin in human keratinocytesExperimental Dermatology, 2003
- The Pseudomonas aeruginosa genome How do we use it to develop strategies for the treatment of patients with cystic fibrosis and Pseudomonas infections?Current Opinion in Pulmonary Medicine, 2002
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermisBritish Journal of Dermatology, 1990